拉斯维加斯(9888·VIP认证)游戏官网-Web Game Platform

1.小分子靶向抗肿瘤药物研发及机制研究
2.放疗增敏剂的筛选及活性评价
3.放化疗保护剂研发及机制研究

1. Guoquan Wan, Zhanzhan Feng, Qiangsheng Zhang, Xiao Li, Kai Ran, Huan Feng, Tianwen Luo, Shuyan Zhou, Chang Su, Wei Wei, Ningyu Wang, Chao Gao, Lifeng Zhao,* and Luoting Yu, Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer, J. Med. Chem, 2022, 65(24):16541-16569.(IF:8.039)
2. Chaoguo Cao, Jie Yang, Yong Chen, Peiting Zhou, Yingwei Wang, Wu Du, Lifeng Zhao,*and Yuanwei Chen, Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers. J. Med. Chem, 2020, 63(19): 11012-11033. (IF:8.039)
3. Zhan Miao, Deng Yu, Lifeng Zhao*,Guoyi Yan, Fangying Wang, Ye Tian, Lanxi Zhang, Hongxia Jiang, and Yuanwei Chen, Design, synthesis, and biological evaluation of dimorpholine substituted thienopyrimidines as potential class I PI3K/mTOR dual inhibitors. J. Med. Chem, 2017, 60, 9: 4023-4035. (IF:8.039)
4. Lidan Zhang; Wen Ren; Xiaoyan Wang; Jiaying Zhang; Jie Liu; Lifeng Zhao*; Xia Zhang; Discovery of novel polycyclic spiro-fused carbocyclicoxindole-based anticancer agents, Eur J Med Chem, 2017, 126: 1071-1082. (IF: 7.088)
5. Fangying Wang , Zhuoling Li , Tao Zhang, Guoyi Yan, Mingxing Hu, Lifeng Zhao*, Yinglan Zhao, Yuanwei Chen. Discovery of a novel class of pyridine derivatives that selectively inhibits mutant Isocitrate dehydrogenase 2. Chem Biol Drug Des, 2017. (IF:2.548)
6. Yingwei Wang, Yufang Deng, Xuehai Pang, Jiang Yu, Lei Fan, Yuanwei Chen and Lifeng Zhao*, Novel thiohydantoin analogues bearing the 1-hydroxyl-2, 2, 2-trifluoro-1-ethyl moiety as androgen receptor inhibitors for the potential treatment of castration resistant prostate cancer. RSC Advances, 2017, 7,51: 31866-31874. (IF: 4.036)
7. Tinghong Ye; Shirui Zhu; Yongxia Zhu; Qiang Feng; Bing He; Yiong Xiong; Lifeng Zhao*; Yiwen Zhang, Luoting Yu; Li Yang; Cryptotanshinone induces melanoma cancer cells apoptosis via ROS-mitochondrial apoptotic pathway and impairs cell migration and invasion, Biomed. Pharmacother., 2016, 82: 319-326.(IF: 7.419)
8. Hong-bao Sun, Xiao-yan Wang, Guo-bo Li,a Li-dan Zhang, Jie Liu and Li-feng Zhao*, Design, synthesis and biological evaluation of novel C3-functionalized oxindoles as potential Pim-1 kinase inhibitors, RSC Advances., 2015, 5, 29456–29466. (IF: 4.036)
9. Ruixue Xu; Miao Zhan; Lingling Peng; Xuehai Pang; Jun Yang; Tao Zhang; Hongxia Jiang; Lifeng Zhao*; Yuanwei Chen∗；Design, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic properties, J Labelled Comp Radiopharm, 2015, 58(7): 308-312.(IF: 1.949)
10. Hong-bao Sun; Xiao-yan Wang; Guo-bo Li; Li-dan Zhang; Jie Liu; Li-feng Zhao*; Design, synthesis and biological evaluation of novel C3-functionalized oxindoles as potential Pim-1 kinase inhibitors, RSC Advances, 2015, 5: 29456–29466.(IF: 4.036)
11. Zhao Lifeng; Li Xiao; Zhang Lidan; Ye Tinghong; Zhu Yongxia; Wei Yuquan; Yang Shengyong; Yu Luoting*, Novel small molecules as apoptosis inducers: synthesis preliminary structure-activity relationships and in vitro biological evaluation, Bioorg. Med. Chem. Lett.，2013, 23: 2293-2297.(IF: 2.940)
12. Lifeng Zhao, Dejun Fei, Yagu Dang, Xiaolong Zhou, Jiali Xiao. Studies on the extraction of chromium(III) by emulsion liquid membrane, J. Hazard. Mater, 2010, 178(1–3): 130-135. (IF:10.588)

纵向课题：
1.主持四川省科技厅应用基础项目，《新型EZH2抑制剂的优化合成及对去势抵抗性前列腺癌转移的机制研究》，19YYJC0761，2019-2021。
2.主持成都市科技局产业集群项目，《新型PI3K/mTOR双靶点抑制剂设计、合成及活性评价》，2016-XT00-00024-GX，2016-2019。
3.主持四川省科技支撑计划项目，《1.1类靶向抗肿瘤新药的开发》，2014SZ0118-SCDX，2014-2017。
授权专利：
1. 嘌呤系列衍生物及其制备方法和用途。2021，中国专利ZL201811205782.7
2. 吲哚酮衍生物及其制药用途，2022，中国专利ZL202011467844.9
3. 具有抗癌作用的氘代嘧啶衍生物，2022，中国专利ZL201910002647.0